CASPIAN — Durvalumab ± Tremelimumab With Platinum-Etoposide in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Phase 3 · 2019 · Small Cell Lung Cancer

Design

Randomized open-label trial of durvalumab plus platinum-etoposide versus platinum-etoposide alone (a third arm added tremelimumab).

Population

Treatment-naive extensive-stage small cell lung cancer.

Primary Endpoint

overall survival (OS)

Key Result

OS 13.0 vs 10.3 months (HR 0.73); benefit sustained at 3 years (17.6% vs 5.8% alive).

Guideline Impact

NCCN category 1 durvalumab plus platinum-etoposide for extensive-stage SCLC